<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380665</url>
  </required_header>
  <id_info>
    <org_study_id>Prevena2009-45</org_study_id>
    <nct_id>NCT01380665</nct_id>
  </id_info>
  <brief_title>Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty</brief_title>
  <acronym>Prevena2009-45</acronym>
  <official_title>Prospective, Single Arm, Post-Marketing Trial to Examine the Safety and Functionality of the Prevena™ Incision Management System, A Negative Pressure Based Surgical Wound Management System, Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KCI USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this study is to evaluate the Prevena ™ 125 Unit and dressing system, when
      applied to either the hip or knee area over a surgical cut for the time you are hospitalized.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative pressure environment with accurate and reliable indicators;Dressing biocompatible with incision site and skin;Minimal dressing changes during therapy;Acceptable safety profile; minimal/no AEs;Patient comfort and dressing integrity after surgery</measure>
    <time_frame>during hospitalization (up to 7 days) and thru follow-up 30 days after dressing removal</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Linear or Emi-linear Incisions</condition>
  <condition>Total Hip Arthroplasty</condition>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>There is one group of 100 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena Incisional Management System</intervention_name>
    <description>All evaluable patients will utilize the Prevena Incisional Management System</description>
    <arm_group_label>There is one group of 100 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be ≥ 18 years of age

          2. Subject must, at the treating physician's determination and definition, be an
             appropriate Candidate for primary total hip or knee arthroplasty

          3. Subjects who undergo primary total knee or hip arthroplasty must have a linear or
             semi-linear incision whose length and curvature should fit within the dimensions bound
             by the polyurethane foam (10 inches in length by 2.5 inches in width)

          4. Subject is able and willing to provide written informed consent and comply with visit
             schedule

          5. Subject must agree to avoid application of tanning lotions or exposure of ultraviolet
             radiation from sun or artificial sources such as a tanning bed on operative area for
             the duration of study participation

          6. Subject must not be pregnant if of child-bearing potential, or otherwise must be
             surgically sterilized or unable to conceive. All females, regardless of child-bearing
             potential, will receive a urine hCG test 2 weeks prior to surgery and the test result
             must be negative for pregnancy.

          7. Subjects who are of child-bearing potential must be utilizing an acceptable method of
             birth control (eg, birth control pills, condom with spermicide, diaphragm with
             spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc) and be
             willing to continue birth control for duration of study participation. If birth
             control method is the form of birth control pills, shots, implants skin patches, or
             IUD, the method must have been utilized for at least 30 days prior to study
             participation.

          8. Subject must be willing to wear loose fitting clothing for duration of treatment
             period

          9. Subject must be willing to comply with visit schedule for the duration of the study

        Exclusion Criteria:

          1. Positive pregnancy test confirmed by hCG in urine

          2. Current or past (30 days prior to surgery) within time of screening attempts to become
             pregnant

          3. Current local or systemic infection (eg, skin infections, sinus infections, urinary
             tract infection, sepsis, etc)

          4. Current or past (14 days prior to surgery) within time of screening topical treatments
             on operative area (eg, laser hair or tattoo removal, sunless tanning lotions)

          5. Current or past (14 days prior to surgery) steroid topical therapies on operative area

          6. Current or past (30 days prior to surgery) use of oral steroids (NOTE: Use of
             non-topical, ophthalmic or aerosol types of steroids (ie, inhaled corticosteroids) are
             permitted at screening and throughout the clinical trial)

          7. Current or past (72 hours prior to surgery) within surgery use of antihistamines

          8. Current or past (30 days prior to surgery) within time of screening use of oral
             Tetracycline or AcutaneTM or topical Tetracycline or AcutaneTM on the operative area

          9. Presence of skin lesions or abnormalities on operative area

         10. Current or past malignancy requiring immunosuppressant therapy or chemotherapy within
             5 years within time of screening

         11. Presence of excessive skin folds on operative area

         12. Intentional exposure of the operative area to ultraviolet radiation (14 days prior to
             surgery) within time of screening (ie, sunbathing or tanning bed)

         13. Presence of sunburned or peeling skin on operative area

         14. Tattoos on operative area

         15. Presence of severe, raised scar tissue on operative area which may interfere with pre
             and post skin evaluation assessments

         16. Presence of an open wound prior to the index surgical procedure on operative area

         17. Reported alcohol (≥ 3 drinks per day) or drug abuse within the past 6 months

         18. Topical hypersensitivity or allergy to any disposable components of the dressing
             system (eg, silver, polyurethane, polyester, or acrylic adhesive)

         19. Topical hypersensitivity or allergy towards any medical adhesive

         20. Current enrollment or past participation in this clinical study or any other study
             within ≤30 days

         21. Any systemic or local active dermatological disease that might interfere with the
             evaluation of the operative area (eg, Meleney's ulcer, scleroderma, chronic urticaria,
             psoriasis, skin cancer, eczema, seborrhea, or malignancy)

         22. Connective tissue disease or collagen vascular disease (eg, Ehlers-Danlos syndrome,
             systemic lupus erythematosus, rheumatoid arthritis)

         23. Current or history of hematological disorders or conditions (eg, polycythemia vera,
             thrombocythemia, sickle-cell disease)

         24. Any Subject with conditions which can potentially result in abnormally pigmented skin
             (eg, melasma, vitiligo, pityriasis versicolor)

         25. Inability or refusal to wear loose fitting clothing for the duration of the treatment
             period

         26. Subjects in whom orthopaedic reconstruction is required in addition to total hip or
             knee arthroplasty

         27. Subjects who are having the total hip or knee arthroplasty as a result of acute
             orthopaedic trauma

         28. Subjects who have incurred acute orthopaedic trauma (ie, hip fracture) recently or at
             any time

         29. Subjects who have either acute or chronic open/active wounds present (including
             biopsies, ulcerations, etc)

         30. Subjects in whom the index procedure is a revision of a total hip or knee arthroplasty

         31. Subjects in whom the primary or partial total hip or knee arthroplasty would also be
             performed on the contra lateral knee or hip at the same time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevena</keyword>
  <keyword>Incision</keyword>
  <keyword>Management</keyword>
  <keyword>System</keyword>
  <keyword>total</keyword>
  <keyword>knee</keyword>
  <keyword>hip</keyword>
  <keyword>replacement</keyword>
  <keyword>Surgery</keyword>
  <keyword>Negative</keyword>
  <keyword>Pressure</keyword>
  <keyword>dressing</keyword>
  <keyword>KCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

